Cardio Diagnostics Holdings, Inc.

CDIO ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021
Revenue $14.8K $34.9K $17.1K $950 $901
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $641.2K $228.0K $145.2K $40.4K $31.5K
SG&A Expense $5.0M $6.9M $6.9M $4.4M $470.6K
Operating Income $-6.5M $-8.4M $-7.2M $-4.5M $-620.4K
Operating Margin -43,737.5% -23,977.9% -42,440.4% -478,784.3% -68,862.2%
Interest Expense $14.8K $18.6K $6.7M
Pretax Income $-6.5M $-8.4M $-8.4M $-4.7M $-620.4K
Income Tax Expense $0 $0
Net Income $-6.5M $-8.4M $-8.4M $-4.7M $-620.4K
Net Margin -43,832.5% -24,028.2% -49,087.8% -490,630.0% -68,862.2%
EPS (Basic) $-3.71 $-9.35 $-0.66 $-0.38 $-0.04
EPS (Diluted) $-3.71 $-9.35 $-0.66 $-0.38 $-0.04
Shares Outstanding (Basic) 3.0M 1.8M 896.4K 12.7M 12.4M 14.0M
Shares Outstanding (Diluted) 3.0M 1.8M 896.4K 12.7M 12.4M 14.0M
Dividends Per Share